Genmab A/S: Genmab Announces Financial Results for the First Half of 2026
Genmab reported first-half 2026 revenue of $2,051 million, up 25% from $1,640 million a year earlier, driven by higher DARZALEX and Kesimpta royalties and higher EPKINLY net product sales. Royalty revenue rose to $1,708 million. Genmab updated 2026 guidance, citing higher DARZALEX royalties and EPKINLY net sales, and noted positive Phase 3 data for epcoritamab plus lenalidomide.
How this was made
The 30-second read
Why it matters
The key tradable items are the 1H revenue/royalty growth and the revised full-year guidance ranges, which can drive estimate revisions and near-term positioning ahead of the earnings call.
Market read
Guidance revision plus disclosed 1H financials provide a concrete basis for re-rating GMAB’s 2026 earnings power, especially via royalty-linked revenue.
What to watch
The guidance update is tied to DARZALEX and EPKINLY performance; traders should watch for any subsequent partner channel checks or regulatory/label changes that could alter those sales trajectories.
Background
Genmab’s interim report covers six months ended June 30, 2026, highlighting clinical Phase 3 progress and financial performance with an updated 2026 outlook.
Ticker impact
Genmab reported 1H 2026 revenue up 25% to $2,051m and updated 2026 guidance, driven by higher DARZALEX and EPKINLY royalties/net sales.
Likely positive near-term bias as traders reprice 2026 royalty and adjusted operating profit expectations; magnitude depends on how the revised guidance compares to Street consensus.
The article discloses specific 1H financials and a revised 2026 outlook, including revenue, royalties, and adjusted operating profit ranges, plus clinical Phase 3 progress for epcoritamab.
Market effects
Reinforces read-through for oncology antibody and bispecific royalty models, where late-stage clinical progress can translate into higher partner sales and royalties.
Limited direct regional spillover beyond European biotech sentiment, unless guidance revisions shift broader expectations for royalty-heavy models.
Global relevance via partner-linked revenue (DARZALEX and Kesimpta royalties), which can affect sentiment across large pharma-biotec collaboration ecosystems.
Counterpoint
Royalty growth may be partially offset by higher cost of product sales and ongoing investment, so equity upside could be capped if pipeline execution or partner sales slow later in 2026.
Key entities
- companyGenmab A/S
Reported 1H 2026 financial results, positive Phase 3 epcoritamab data, and updated 2026 guidance.
- productDARZALEX
Partner-linked product whose net sales by J&J drove higher Genmab royalties in 1H 2026.
- productKesimpta
Partner-linked product whose net sales contributed to higher Genmab royalty revenue in 1H 2026.
- productEPKINLY/TEPKINLY
Genmab net product sales increased in 1H 2026 and are cited as a driver of improved 2026 guidance.
- product_candidateRina-S (rinatabart sesutecan)
New data support development in advanced ovarian cancer; cited as part of pipeline investment.
